Announcement • Jul 22
Jushi Holdings Inc. to Report Q2, 2026 Results on Jul 28, 2026 Jushi Holdings Inc. announced that they will report Q2, 2026 results After-Market on Jul 28, 2026 Announcement • May 28
Jushi Holdings Inc. Submits Applications to the U.S. Drug Enforcement Administration for Registration of State-Licensed Medical Cannabis Operations Jushi Holdings Inc. announced that it has submitted applications to the U.S. Drug Enforcement Administration seeking registration for certain state-licensed medical marijuana operations under the federal framework established following the rescheduling of medical marijuana to Schedule III under the Controlled Substances Act. In connection with the reclassification of medical marijuana produced by state-licensed operators to Schedule III, the Drug Enforcement Administration introduced a streamlined registration pathway for qualified state-licensed medical marijuana operators. This process enables applicants to seek federal registration in connection with the manufacture, distribution, and dispensing of Schedule III medical cannabis products, while relying on existing state medical licenses as part of the qualification process. For operators that submit applications within the initial 60-day filing window, registrations may be granted on an expedited basis unless otherwise notified by the Drug Enforcement Administration. Jushi believes this framework reflects growing federal recognition of the strength and oversight of state medical cannabis programs and provides a pathway toward greater alignment between state and federal regulation. The Company’s applications are intended to position Jushi to participate in this evolving regulatory structure while continuing to serve medical patients in accordance with applicable state laws. Reported Earnings • May 14
First quarter 2026 earnings: EPS misses analyst expectations First quarter 2026 results: US$0.10 loss per share (further deteriorated from US$0.087 loss in 1Q 2025). Revenue: US$66.4m (up 4.1% from 1Q 2025). Net loss: US$19.8m (loss widened 17% from 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 86%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • May 06
Jushi Holdings Inc., Annual General Meeting, Jun 24, 2026 Jushi Holdings Inc., Annual General Meeting, Jun 24, 2026. Announcement • May 05
Jushi Holdings Inc. to Report Q1, 2026 Results on May 12, 2026 Jushi Holdings Inc. announced that they will report Q1, 2026 results After-Market on May 12, 2026 New Risk • Apr 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$115m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$6.3m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$133.8m market cap, or US$97.9m). Reported Earnings • Apr 04
Full year 2025 earnings released: US$0.35 loss per share (vs US$0.25 loss in FY 2024) Full year 2025 results: US$0.35 loss per share (further deteriorated from US$0.25 loss in FY 2024). Revenue: US$262.9m (up 2.1% from FY 2024). Net loss: US$68.6m (loss widened 41% from FY 2024). Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Mar 28
Jushi Holdings Inc. to Report Q4, 2025 Results on Mar 31, 2026 Jushi Holdings Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 31, 2026 New Risk • Feb 12
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: CA$136.1m (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-US$101m). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$49m net loss next year). Market cap is less than US$100m (CA$136.1m market cap, or US$99.9m). New Risk • Dec 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-US$101m). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$49m net loss next year). Market cap is less than US$100m (CA$135.0m market cap, or US$98.1m). Buy Or Sell Opportunity • Nov 16
Now 28% undervalued after recent price drop Over the last 90 days, the stock has fallen 26% to CA$0.64. The fair value is estimated to be CA$0.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.0% over the last 3 years. Earnings per share has grown by 44%. Revenue is forecast to grow by 9.3% in a year. Earnings are forecast to grow by 24% in the next year. Announcement • Nov 13
Jushi Holdings Launches Shayo Cannabis-Infused Fruit Chews In Nevada Adult-Use Market Jushi Holdings Inc. announced the expansion of Shayo — the cannabis-infused wellness brand co-created with entrepreneur, philanthropist, and Real Housewives of Potomac star Stacey Rusch — into the Nevada Adult-Use Market beginning Thursday, November 13th. After achieving success in Virginia’s medical market, Shayo is bringing its elevated, cannabis-infused fruit chews to Nevada consumers aged 21 and over. Two distinct cannabis-infused fruit chews are now available, each designed with a target cannabinoid profile and thoughtful flavor pairing. Set your intention for the day with Rise (Blood Orange Pomegranate), showcasing a 1:2 THC:CBG ratio, or unwind with Rest (Berry Vanilla), featuring a 1:2 THC:CBN ratio to help you relax and recharge. Both varieties are vegan, gluten-free, non-GMO, and made with natural fruit purées, delivering a premium, functional edible experience. Shayo products will be available for purchase starting Thursday, November 13th at NuLeaf Las Vegas and Incline Village, Beyond Hello Las Vegas and will be coming soon to additional Nevada licensed retailers. Reported Earnings • Nov 06
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: US$0.12 loss per share (further deteriorated from US$0.082 loss in 3Q 2024). Revenue: US$65.7m (up 6.6% from 3Q 2024). Net loss: US$23.7m (loss widened 48% from 3Q 2024). Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 145%. Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Board Change • Nov 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Bill Wafford was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 22
Jushi Holdings Inc. to Report Q3, 2025 Results on Nov 04, 2025 Jushi Holdings Inc. announced that they will report Q3, 2025 results on Nov 04, 2025 Buy Or Sell Opportunity • Oct 10
Now 22% undervalued Over the last 90 days, the stock has risen 62% to CA$1.07. The fair value is estimated to be CA$1.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.8% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 8.8% in a year. Earnings are forecast to grow by 18% in the next year. Reported Earnings • Aug 06
Second quarter 2025 earnings: EPS exceeds analyst expectations Second quarter 2025 results: US$0.063 loss per share (further deteriorated from US$0.01 loss in 2Q 2024). Revenue: US$65.0m (flat on 2Q 2024). Net loss: US$12.3m (loss widened US$10.4m from 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 9.1%. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Announcement • Jul 23
Jushi Holdings Inc. to Report Q2, 2025 Results on Aug 05, 2025 Jushi Holdings Inc. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025 New Risk • Jul 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-US$66m). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$52m net loss next year). Market cap is less than US$100m (CA$98.9m market cap, or US$72.4m). Announcement • Jun 24
Jushi Holdings Inc. Announces Launch of Lifestyle Cannabis Brand 'Shayo' Jushi Holdings Inc. has partnered with entrepreneur, philanthropist, and Real Housewives of Potomac star Stacey Rusch on a new cannabis-infused wellness brand, Shayo. Shayo, named after the Nigerian term meaning "to be happy," blends elevated ingredients with a lifestyle-forward ethos to deliver a one-of-a-kind edible experience to Virginia's medical cannabis market. Two distinct rosin-infused fruit chews are now available, each designed with a target cannabinoid profile and thoughtful flavor pairing. Set intention for the day with Rise(Blood Orange Pomegranate), in which bright citrus and tart pomegranate intertwine, giving a complex flavor that is grounded and strikes a remarkable balance. Rise showcases a unique 1:2 ratio of THC:CBG. Manifest your perfect dreamscape with Rest (Berry Vanilla), in which red and dark berry flavors fold into soft and floral vanilla tones that are ideal to wrap up any day. The 1:2 ratio ofTH:CBN helps body let go of what no longer serves. Both varieties are vegan, gluten-free, non-GMO, and made with natural fruit purees, offering a premium edible that's as functional as it is flavorful. Price Target Changed • May 12
Price target decreased by 8.8% to CA$0.73 Down from CA$0.80, the current price target is provided by 1 analyst. New target price is 54% above last closing price of CA$0.47. Stock is down 48% over the past year. The company is forecast to post a net loss per share of US$0.24 next year compared to a net loss per share of US$0.25 last year. Reported Earnings • May 10
First quarter 2025 earnings: EPS and revenues miss analyst expectations First quarter 2025 results: US$0.087 loss per share (improved from US$0.094 loss in 1Q 2024). Revenue: US$63.8m (down 2.5% from 1Q 2024). Net loss: US$17.0m (loss narrowed 7.3% from 1Q 2024). Revenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates by 45%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings. New Risk • Apr 30
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$50m). Earnings are forecast to decline by an average of 0.9% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$48m net loss in 2 years). Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (CA$94.0m market cap, or US$68.1m). Announcement • Apr 24
Jushi Holdings Inc. to Report Q1, 2025 Results on May 08, 2025 Jushi Holdings Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025 Announcement • Mar 25
Jushi Holdings Inc., Annual General Meeting, Jun 03, 2025 Jushi Holdings Inc., Annual General Meeting, Jun 03, 2025. Reported Earnings • Mar 07
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: US$0.25 loss per share (improved from US$0.33 loss in FY 2023). Revenue: US$257.5m (down 4.4% from FY 2023). Net loss: US$48.8m (loss narrowed 25% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 21%. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings. Announcement • Mar 04
Jushi Holdings Inc. Announces Resignation of Tobi Lebowitz as Chief Legal Officer and Corporate Secretary, Effective March 28, 2025 On February 26, 2025, Tobi Lebowitz, Chief Legal Officer and Corporate Secretary of Jushi Holdings Inc., resigned from the Company effective March 28, 2025. Mrs. Lebowitz’s resignation did not result from any disagreement with the Company. Price Target Changed • Mar 02
Price target decreased by 16% to CA$1.07 Down from CA$1.26, the current price target is provided by 1 analyst. New target price is 137% above last closing price of CA$0.45. Stock is down 55% over the past year. The company is forecast to post a net loss per share of US$0.21 next year compared to a net loss per share of US$0.33 last year. Announcement • Feb 25
Jushi Holdings Inc. to Report Q4, 2024 Results on Mar 06, 2025 Jushi Holdings Inc. announced that they will report Q4, 2024 results After-Market on Mar 06, 2025 Announcement • Feb 18
Jushi Holdings Inc. announced that it expects to receive $5.1 million in funding Jushi Holdings Inc. announced that it has entered into a subscription agreements for the gross proceeds of $5,100,000 on February 18, 2025. The transaction will include participation new investor, an entity affiliated with James Cacioppo for a purchase price of approximately $3,300,000 and will receive up to 6,200,000 warrants, and individual investor, Denis Arsenault for a notes of principal $1,411,800 at purchase price of $1,270,620 and will receive up to approximately 2,400,000 warrants. The company will issue 12% Second Lien Notes 2026 and detached warrants. The notes will be issued at 10% original issue discount. Each warrant holder is entitled to subscribe the number of fully-paid and non-assessable subordinate voting shares of the company at par value. The company has issued securities pursuant to exemptions provided under Regulation D. The transaction is expected to close with in five days of issuance of notes and warrants. The company will receive net proceeds of $4.6 million. The transaction is approved by board of directors of the company. Announcement • Jan 09
Jushi Holdings Inc. Announces Termination of Todd West as Chief Operating Officer On January 6, 2025, Todd West was terminated as an employee and Chief Operating Officer of Jushi Holdings Inc. and from any other position at any subsidiary of the Company to which he has been appointed. The Company provided Mr. West with notice that his employment was terminated for cause pursuant to his employment agreement, dated April 12, 2024. Mr. West will not receive any salary or benefits from the Company except those earned through January 6, 2025. Mr. West has asserted that his termination was not for cause and that he is owed all salary and benefits provided for in his employment agreement. New Risk • Nov 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$39m). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$38m net loss next year). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (CA$97.1m market cap, or US$69.7m). Price Target Changed • Nov 10
Price target decreased by 7.8% to CA$1.34 Down from CA$1.45, the current price target is provided by 1 analyst. New target price is 173% above last closing price of CA$0.49. Stock is down 54% over the past year. The company is forecast to post a net loss per share of US$0.16 next year compared to a net loss per share of US$0.33 last year. Reported Earnings • Nov 08
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: US$0.082 loss per share (improved from US$0.11 loss in 3Q 2023). Revenue: US$61.6m (down 5.8% from 3Q 2023). Net loss: US$16.0m (loss narrowed 22% from 3Q 2023). Revenue missed analyst estimates by 6.0%. Earnings per share (EPS) also missed analyst estimates by 131%. Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings. Announcement • Oct 24
Jushi Holdings Inc. to Report Q3, 2024 Results on Nov 07, 2024 Jushi Holdings Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024 Reported Earnings • Aug 09
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2024 results: US$0.01 loss per share (improved from US$0.072 loss in 2Q 2023). Revenue: US$64.6m (down 2.8% from 2Q 2023). Net loss: US$1.94m (loss narrowed 86% from 2Q 2023). Revenue missed analyst estimates by 4.4%. Earnings per share (EPS) exceeded analyst estimates by 82%. Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. New Risk • Aug 06
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: CA$128.8m (US$93.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$24m). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$49m net loss next year). Market cap is less than US$100m (CA$128.8m market cap, or US$93.4m). Announcement • Jul 25
Jushi Holdings Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jushi Holdings Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024 Price Target Changed • Jul 09
Price target decreased by 7.1% to CA$1.37 Down from CA$1.48, the current price target is provided by 1 analyst. New target price is 80% above last closing price of CA$0.76. Stock is up 23% over the past year. The company is forecast to post a net loss per share of US$0.28 next year compared to a net loss per share of US$0.33 last year. Announcement • Apr 27
Jushi Holdings Inc. to Report Q1, 2024 Results on May 09, 2024 Jushi Holdings Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024 Announcement • Apr 16
Jushi Holdings Inc. Appoints Todd West as Chief Operating Officer Jushi Holdings Inc. announced that it has appointed Todd West as Chief Operating Officer, effective April 12, 2024. Mr. West brings over 25 years of operations management experience in retail, manufacturing, and wholesale, including five years in cannabis with his most recent role being Executive Vice President of Operations at Cresco Labs Inc. Prior to cannabis, Mr. West was an operations executive for almost a decade in the food and beverage industry directing daily operations including overseeing manufacturing, warehousing, distribution, supply chain, inventory control, new product development, R&D, quality assurance, and retail. Announcement • Mar 26
Jushi Holdings Inc., Annual General Meeting, Jun 04, 2024 Jushi Holdings Inc., Annual General Meeting, Jun 04, 2024. Announcement • Mar 16
Jushi Holdings Inc. announced delayed annual 10-K filing On 03/15/2024, Jushi Holdings Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Reported Earnings • Mar 15
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: US$0.33 loss per share (improved from US$1.07 loss in FY 2022). Revenue: US$269.4m (down 5.2% from FY 2022). Net loss: US$65.1m (loss narrowed 68% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 23%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Mar 04
Now 22% undervalued Over the last 90 days, the stock has risen 1.1% to CA$0.90. The fair value is estimated to be CA$1.16, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to decline by 1.9% in a year. Earnings are forecast to grow by 73% in the next year. Announcement • Feb 29
Jushi Holdings Inc. to Report Q4, 2023 Results on Mar 13, 2024 Jushi Holdings Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Mar 13, 2024 Buy Or Sell Opportunity • Feb 16
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 20% to CA$0.89. The fair value is estimated to be CA$1.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to decline by 1.9% in a year. Earnings are forecast to grow by 73% in the next year. Buying Opportunity • Jan 10
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 24%. The fair value is estimated to be CA$0.97, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to decline by 1.9% in a year. Earnings is forecast to grow by 73% in the next year. Buying Opportunity • Dec 13
Now 25% undervalued after recent price drop Over the last 90 days, the stock is down 30%. The fair value is estimated to be CA$0.92, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to decline by 1.9% in a year. Earnings is forecast to grow by 73% in the next year. Reported Earnings • Nov 17
Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.28 loss in 3Q 2022) Third quarter 2023 results: US$0.11 loss per share (improved from US$0.28 loss in 3Q 2022). Revenue: US$65.4m (down 10% from 3Q 2022). Net loss: US$20.6m (loss narrowed 62% from 3Q 2022). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Price Target Changed • Nov 16
Price target increased by 13% to CA$1.72 Up from CA$1.52, the current price target is an average from 3 analysts. New target price is 56% above last closing price of CA$1.10. Stock is down 53% over the past year. The company is forecast to post a net loss per share of US$0.23 next year compared to a net loss per share of US$1.06 last year. Announcement • Nov 01
Jushi Holdings Inc. to Report Q3, 2023 Results on Nov 14, 2023 Jushi Holdings Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023 New Risk • Oct 29
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: CA$122.7m (US$88.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$28m). Currently unprofitable and not forecast to become profitable next year (US$49m net loss next year). Market cap is less than US$100m (CA$122.7m market cap, or US$88.5m). Recent Insider Transactions • Sep 12
CFO & Chief Accounting Officer recently bought CA$68k worth of stock On the 7th of September, Michelle Mosier bought around 67k shares on-market at roughly CA$1.03 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Michelle's only on-market trade for the last 12 months. Reported Earnings • Aug 13
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2023 results: US$0.072 loss per share (down from US$0.063 profit in 2Q 2022). Revenue: US$66.4m (down 8.7% from 2Q 2022). Net loss: US$14.0m (down 216% from profit in 2Q 2022). Revenue missed analyst estimates by 7.0%. Earnings per share (EPS) exceeded analyst estimates by 35%. Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Announcement • Jul 29
Jushi Holdings Inc. to Report Q2, 2023 Results on Aug 11, 2023 Jushi Holdings Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 11, 2023 Price Target Changed • Jun 24
Price target decreased by 29% to CA$1.77 Down from CA$2.49, the current price target is an average from 3 analysts. New target price is 156% above last closing price of CA$0.69. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$0.26 next year compared to a net loss per share of US$1.06 last year. Reported Earnings • May 13
First quarter 2023 earnings: EPS in line with expectations, revenues disappoint First quarter 2023 results: US$0.064 loss per share (improved from US$0.11 loss in 1Q 2022). Revenue: US$69.9m (up 13% from 1Q 2022). Net loss: US$12.4m (loss narrowed 37% from 1Q 2022). Revenue missed analyst estimates by 5.9%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 04
Price target decreased by 23% to CA$2.49 Down from CA$3.24, the current price target is an average from 4 analysts. New target price is 261% above last closing price of CA$0.69. Stock is down 81% over the past year. The company is forecast to post a net loss per share of US$0.46 next year compared to a net loss per share of US$1.06 last year. Reported Earnings • Apr 02
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: US$1.07 loss per share (down from US$0.14 profit in FY 2021). Revenue: US$284.3m (up 36% from FY 2021). Net loss: US$202.3m (down US$226.5m from profit in FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 175%. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Price Target Changed • Feb 15
Price target decreased by 14% to CA$3.71 Down from CA$4.29, the current price target is an average from 4 analysts. New target price is 271% above last closing price of CA$1.00. Stock is down 82% over the past year. The company is forecast to post a net loss per share of US$0.42 compared to earnings per share of US$0.15 last year. Announcement • Jan 22
Jushi Holdings Inc. Announces Resignation of James Cabral as Chief Accounting Executive, Effective February 3, 2023 On January 16, 2023, James Cabral, Chief Accounting Executive of Jushi Holdings Inc. (the "Company"), resigned from the Company effective February 3, 2023. Mr. Cabral’s resignation did not result from any disagreement with the Company. On January 17, 2023, the Board of Directors of the Company appointed Michelle Mosier as Chief Accounting Officer of the Company in addition to her existing role as Chief Financial Officer of the Company. Announcement • Jan 14
Jushi Holdings Inc., Annual General Meeting, Jun 14, 2023 Jushi Holdings Inc., Annual General Meeting, Jun 14, 2023. Announcement • Dec 23
Jushi Holdings Inc. announced that it has received $32.436 million in funding On December 22, 2022, Jushi Holdings Inc. closed the transaction. The transaction included participation from 34 investors. Announcement • Dec 09
Jushi Holdings Inc. announced that it has received $69 million in funding On December 8, 2022, Jushi Holdings Inc. closed the transaction. The company has received $1,000,000 in its second and last tranche. The company has received $69,000,000 in its 12% second lien notes and detached warrants to purchase up to approximately 16,000,000 of the company’s subordinate voting shares at an exercise price of $2.086. The company has also received subscriptions for an additional $5 million to be closed at a later date. The notes will mature on December 7, 2026, will bear interest of 12% per annum, payable in cash quarterly, and will be guaranteed by certain of the company’s direct and indirect domestic subsidiaries and secured by second priority liens on certain assets of the company and certain of the company’s direct and indirect domestic subsidiaries. In connection with the offering, the purchasers of the notes also received four-year warrants at 50% coverage with an expiry date of December 7, 2026, at an exercise price per share equal to $2.086. The interest payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year, beginning on December 31, 2022. Announcement • Nov 17
Jushi Holdings Inc. announced a financing transaction Jushi Holdings Inc. announced that it has received binding subscriptions for private placement of 12% second lien notes on November 15, 2022. The transaction will include participation from entities affiliated with Jim Cacioppo, Jushi’s Chief Executive Officer, Chairman and Founder, subscribed for $3,000,000 of the notes, and Denis Arsenault, a significant stockholder of the company subscribing for $13,400,000 of the notes. Pursuant to the terms of the offering the company may issue additional notes on the same terms, subject to market conditions and investor interest. The notes will mature four years from the date of issuance, will bear interest of 12% per annum, payable in cash quarterly, and will be guaranteed by certain of the company’s direct and indirect domestic subsidiaries and secured by second priority liens on certain assets of the company and certain of the company’s direct and indirect domestic subsidiaries. In connection with the offering, the purchasers of the notes will also receive four-year warrants to acquire subordinate voting shares of the company at 50% coverage with an exercise price to be determined at closing. The company expects the closing of the offering to occur in late November or early December of this year. Securities issued will be subject to a statutory hold period lasting four months and one day following the closing date pursuant to applicable Canadian securities laws. The notes and related guarantees and warrants will be offered and sold in a private placement only to U.S. accredited investors and/or qualified institutional buyers in reliance on the registration exemption provided by Rule 506(b) of Regulation D under the U.S. Securities Act and/or Section 4(a)(2) of the U.S. Securities Act.
On the same date, the company received $68,000,000 in its first tranche close. Announcement • Nov 16
Jushi Holdings Inc. announced delayed 10-Q filing On 11/15/2022, Jushi Holdings Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Price Target Changed • Nov 16
Price target decreased to CA$4.42 Down from CA$5.17, the current price target is an average from 4 analysts. New target price is 94% above last closing price of CA$2.28. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$0.23 compared to earnings per share of US$0.15 last year. Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improved over the past week After last week's 16% share price gain to CA$2.44, the stock trades at a trailing P/E ratio of 8x. Average forward P/E is 2x in the Pharmaceuticals industry in Canada. Total returns to shareholders of 22% over the past three years. Announcement • Nov 01
Jushi Holdings Inc. to Report Q3, 2022 Results on Nov 14, 2022 Jushi Holdings Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 14, 2022 Price Target Changed • Oct 31
Price target decreased to CA$5.17 Down from CA$5.80, the current price target is an average from 4 analysts. New target price is 123% above last closing price of CA$2.32. Stock is down 51% over the past year. The company is forecast to post a net loss per share of US$0.27 compared to earnings per share of US$0.15 last year. Announcement • Oct 28
Jushi Holdings Inc. Launches Newly Formulated Cannabis Infused Fruit Chews by Tasteology Jushi Holdings Inc. announced it has debuted its newly formulated vegan and gluten-free Tasteology Fruit Chews in Massachusetts, and expects to roll out the new product line in Virginia, Ohio and Nevada in First Quarter 2023. Made with the finest real fruit purées by Ponthier, and crafted by Jushi's Director of Manufacturing and Bravo's Top Chef: Just Desserts finalist, Matthew Petersen, along with Jushi's Product Development Team, Tasteology Fruit Chews are now available in three new varieties -- Blood Orange Boost, Blueberry Calm and Passion Raspberry Balance - at Nature's Remedy dispensaries in Tyngsborough and Millbury, Massachusetts, and will continue to rollout to partner dispensaries in the coming months. Containing no colorings, preservatives or artificial flavors, each package of Tasteology Fruit Chews includes 20 chews, each with 5mg of THC, unique terpene blends and minor cannabinoids like CBD and CBN for specific experiences. Tasteology Fruit Chews are made from real fruit purées and use pectin rather than gelatin to deliver a consumption experience with more experience-focused terpenes. In addition, Jushi updated the brand's packaging with new Tarot card-theme branding and sustainable pouches rather than the more commonly used tins, which use less waste and preserve freshness better. Valuation Update With 7 Day Price Move • Oct 11
Investor sentiment improved over the past week After last week's 44% share price gain to CA$2.47, the stock trades at a trailing P/E ratio of 7.8x. Average forward P/E is 11x in the Pharmaceuticals industry in Canada. Total returns to shareholders of 27% over the past three years. Announcement • Oct 05
Jushi Holdings Inc. Announces Appoints Bill Wafford to Its Board of Directors, Effective Immediately Jushi Holdings Inc. announced that it has appointed Bill Wafford to its Board of Directors, effective immediately. In addition to his appointment as Independent Director, Mr. Wafford will serve as Chair of the Audit Committee. Mr. Wafford is a highly skilled leader with over 25 years of finance and management consulting experience. Over the course of his career, he has led all aspects of finance, strategy, and execution within several Fortune 500 public and private companies in the retail industry. His deep breadth of experience spans various functions, including accounting, corporate venture capital, M&A, and real estate, in addition to corporate strategy, investor relations, internal audit functions, and procurement and supply chain management. Mr. Wafford currently serves as Chief Financial Officer of Everlane, a digitally native apparel, footwear and accessories brand that is leading the fashion industry toward a more environmentally conscious sustainable future. Prior to Everlane, he served as Chief Financial Officer of JCPenney, one of the largest retail department chains in the U.S., The Vitamin Shoppe, a specialty retailer of nutritional products, and Thrasio, a global consumer goods company. Mr. Wafford also previously served as Partner of the advisory practice group at KPMG, after holding various executive finance roles with Walgreens Boots Alliance, Target, Archstone Consulting, and Bank of America. Management Update: The Company also announced that it has bolstered its senior leadership team with the promotion of Tobi Lebowitz to Chief Legal Officer and Corporate Secretary. Ms. Lebowitz joined the Company in 2019 and was part of the core team which brought Jushi public shortly thereafter. Since then, she has played an instrumental role in the execution of various initiatives across the business, including strategic M&A, business development, and high-stakes litigation. Ms. Lebowitz previously held the role of Executive Vice President and Co-Head of Legal Affairs. Announcement • Sep 08
Jushi Debuts Cannabis-Infused Chocolates by Tasteology Jushi Holdings Inc. announced the launch of cannabis-infused chocolates by Tasteology in Massachusetts. The debut of the Company's latest product line, which has been handcrafted by Jushi’s Director of Manufacturing and Bravo’s Top Chef: Just Desserts finalist, Matt Petersen, in concert with Jushi’s product development team, marks the Company’s entrance into the cannabis-infused chocolates market. Artfully crafted from 100% gourmet chocolate made with responsibly sourced cocoa beans from gourmet French chocolatier, Valrhona, Tasteology Chocolates are currently available in three flavors: Milk Chocolate, Dark Chocolate and Strawberry The chocolates are also 100% Fair Trade and USDA Organic Certified, using beans that have been sourced only from suppliers that embrace agroforestry and adhere to a strict charter that was designed to protect labor rights, biodiversity and food safety. Blonde Chocolate. These 18-piece bars, which are easily separable for accurate dosing, contain 90mg of THC per bar [5mg per piece]. As cannabis markets mature, the demand for edibles has grown at an outpaced rate relative to overall industry growth. According to cannabis point-of-sale software provider Flowhub, in 2021, the edibles category made up 11% of overall sales, compared to 9% in 2020, representing $2.75B. Coupled with results from Jushi’s inaugural “4/20 Cannabis Insights Poll,” which found that out of any product category, non-cannabis users would be most interested in trying edibles (32.7%), the demand for edibles remains strong and is likely to keep growing. Announcement • Aug 30
Jushi Holdings Inc. Revises Earnings Guidance for the Fourth Quarter of 2022 Jushi Holdings Inc. revised earnings guidance for the fourth quarter of 2022. The company is revising fourth quarter 2022 annualized revenue to be between $320 to $350 million. Announcement • Aug 03
Jushi Holdings Inc. to Report Q2, 2022 Results on Aug 29, 2022 Jushi Holdings Inc. announced that they will report Q2, 2022 results on Aug 29, 2022 Announcement • Jul 12
Jushi Holdings Inc. Announces Grand Reopening of Beyond Hello(TM) Palm Springs Jushi Holdings Inc. announced the grand reopening of its Beyond Hello (TM) Palm Springs retail location will be held on July 13, 2022 at 9:00 a.m. PT. Open every day from 9:00 a.m. to 9:00 p.m., Beyond Hello(TM) Palm Springs shoppers can choose from a wide variety of product selections from California craft cannabis providers and distinctive finds, such as the Company's signature scented candle, which Jushi designed in collaboration with a locally owned company Joshua Tree Candle Co. ("JTC") to capture the scents and sentiment of California's Joshua Tree - a legendary travel destination amongst nature enthusiasts. In addition, shop-goers can find popular cannabis brands and products, including flower, concentrates, vaporization products, tinctures, edibles, topicals, capsules, pills and various ancillary products, such as approved rigs, batteries, merchandise and other devices. Beyond Hello(TM) Palm Springs features an express pickup option, 12 point-of-sales systems five of which are express and 22 convenient parking spots. As part of the Company's commitment to exceeding customer expectations, an experienced well-trained staff will be on-site to help dispense products, answer questions and provide exceptionalservice. Valuation Update With 7 Day Price Move • Jul 07
Investor sentiment improved over the past week After last week's 21% share price gain to CA$2.26, the stock trades at a trailing P/E ratio of 7.9x. Average forward P/E is 6x in the Pharmaceuticals industry in Canada. Total loss to shareholders of 68% over the past year. Announcement • Jun 30
Jushi Holdings Inc. Debuts Line of Concentrate Products Using Hydrocarbon Extraction Diversifying Its Offering of the Lab™ Vape and Concentrate Products Jushi Holdings Inc. debuted its first line of concentrates made using hydrocarbon extraction by its award-winning brand The Lab™, famous for delivering high-quality, precision vape products and concentrates. The Lab™ Live Resin is the second of several single-source concentrate product lines to be launched by Jushi. Last month, the Company launched its first line of solventless live rosin extracts. Initially, Jushi will exclusively carry The Lab™ Live Resin 500mg full-spectrum 0.5 gram 510 cartridges at Beyond Hello™ retail locations in Pennsylvania. The Company plans to roll out its hydrocarbon-extracted line at partner dispensaries across the Commonwealth in the coming months, as well as in additional states such as Massachusetts, Virginia and Nevada. The Company also plans to launch a 300mg rechargeable, all-in-one 0.3g vape and a variety of 1 gram jarred cured concentrates in the coming months, pending regulatory approval. The new hydrocarbon extract products are rich in THC, cannabinoids, terpenes and flavonoids, and include roughly 90% of the plant’s original cannabinoids. The Lab™ Live Resin is produced using Jushi’s next-generation hydrocarbon extraction process utilizing high quality fresh frozen cannabis flower. This extraction process allows for the delicate make-up of the cannabis plant to be maintained so that the strain specific cannabinoids and terpene properties remain fully intact. Recent Insider Transactions • Jun 22
Founder recently bought CA$197k worth of stock On the 17th of June, James Cacioppo bought around 100k shares on-market at roughly CA$1.97 per share. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of CA$473k worth in shares. Board Change • May 31
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Founder, Chairman & CEO Jim Cacioppo is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Price Target Changed • May 26
Price target decreased to CA$8.60 Down from CA$9.30, the current price target is an average from 7 analysts. New target price is 257% above last closing price of CA$2.41. Stock is down 67% over the past year. The company is forecast to post a net loss per share of US$0.18 compared to earnings per share of US$0.15 last year. Announcement • May 26
Jushi Holdings Inc. Revises Earnings Guidance for the Fourth Quarter of 2022 Jushi Holdings Inc. revised earnings guidance for the fourth quarter of 2022. The company is modestly revising its fourth quarter 2022 annualized revenue to be between $340 million to $380 million. The slight reduction in revenue guidance was driven by (1) weakening in the macro environment; (2) ongoing regulatory delays; and (3) supply chain issues. Announcement • May 18
Jushi Holdings Inc. Expands Product Offerings with Launch of Its First Line of Solventless Cannabis Extracts Jushi Holdings Inc, launched the company’s first line of solventless live rosin extracts by its award-winning brand The Lab™, famous for delivering high-quality, precision vape products and concentrates. The new top-shelf product line, produced purely from premium flower and extracted simply with ice and water, includes a 0.5g vape extract cartridge available now and 1g jarred concentrates coming soon for purchase exclusively at BEYOND /HELLO™ store locations in Pennsylvania under the name, The Lab™ Solventless Live RSN. In addition, throughout the summer, it is expected to launch at the Company’s locations in Massachusetts, Nevada, and Virginia, pending regulatory approvals. The Lab Solventless Live Rosin expands Jushi’s suite of other branded cannabis products, including The Bank, Sèchè, and Tasteology, and is formulated using premium flower, which is freshly frozen to preserve the plant’s best qualities. The cannabinoid-rich trichomes are isolated and gradually extracted using a proprietary flash-freezing and ice-water gentle extraction process, specifically designed to capture the plant’s coveted cannabinoids, terpenes, and flavonoids. This cannabinoid-rich mixture is then dried and pressed using heat and pressure to produce some of the purest, most sought-after forms of concentrate. As cannabis markets mature and more states come online, the demand for extracted products continues to accelerate. According to leading cannabis market research firm BDSA, the cannabis extract market size was estimated at US$9.24B in 2021 and is projected to increase nearly fivefold, reaching US$42.89 billion by 2030. Reported Earnings • May 05
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: EPS: US$0.14 (up from US$2.11 loss in FY 2020). Revenue: US$209.3m (up 159% from FY 2020). Net income: US$24.1m (up US$234.1m from FY 2020). Profit margin: 12% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Over the next year, revenue is forecast to grow 56%, compared to a 98% growth forecast for the pharmaceuticals industry in Canada. Valuation Update With 7 Day Price Move • May 03
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CA$2.99, the stock trades at a trailing P/E ratio of 17.5x. Average forward P/E is 5x in the Pharmaceuticals industry in Canada. Total loss to shareholders of 66% over the past year. Announcement • Apr 19
Jushi Holdings Inc., Annual General Meeting, Jun 29, 2022 Jushi Holdings Inc., Annual General Meeting, Jun 29, 2022. Announcement • Apr 08
Jushi Holdings Inc. (OTCPK:JUSH.F) completed the acquisition of NuLeaf, Inc. for $53.6 million. Jushi Holdings Inc. (OTCPK:JUSH.F) entered into a definitive agreement to acquire NuLeaf, Inc. for $62.5 million on November 17, 2021. As per the terms, consideration will be paid in the form of $15.75 million in cash, $21 million in subordinate voting shares of Jushi and a $15.75 million unsecured promissory notes. Jushi has also agreed to issue up to an additional $10.0 million in an identical percentage combination of cash, Jushi's shares, and unsecured promissory note upon the occurrence or non-occurrence of the Las Vegas Strip Dispensary receiving the applicable regulatory approvals to commence operations. The transaction is subject to certain customary closing conditions, including approvals from applicable regulatory authorities. The acquisition is expected to close in the first half of 2022. As of March 24, 2022, the transaction is expected to close in April 2022.
Jushi Holdings Inc. (OTCPK:JUSH.F) completed the acquisition of NuLeaf, Inc. for $53.6 million on April 7, 2022. Jushi acquired 100% of NuLeaf’s operational dispensary assets as well as 100% of its cultivation and processing facilities for an upfront payment of $45.0 million, comprised of $15.75 million in cash, $13.53 million in subordinate voting shares of the company and a $15.75 million unsecured promissory note. The company has also agreed to issue up to an additional $8.6 million in an identical percentage combination of cash, company shares, and unsecured promissory note upon the occurrence or non-occurrence of the Las Vegas Strip Dispensary receiving the applicable regulatory approvals to commence operations. Jushi plans to fund the cash portion of the NuLeaf acquisition and the previously closed Apothecarium Nevada acquisition by drawing down on its $100 million Senior Secured Credit Facility. Announcement • Mar 03
Jushi Holdings Inc. to Report Q4, 2021 Results on Mar 24, 2022 Jushi Holdings Inc. announced that they will report Q4, 2021 results Pre-Market on Mar 24, 2022 
